Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 38.20
+3.52 (10.15%)
At close: Mar 27, 2026
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 13.5 billion as of March 27, 2026. Its market cap has decreased by -16.97% in one year.
Market Cap
13.50B
Enterprise Value
11.49B
Revenue
1.90B
Ranking
n/a
PE Ratio
n/a
Stock Price
38.20
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 13.50B, a decrease of -34.61%. That is a compound annual growth rate of -7.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 26, 2026 | 12.25B | -6.22% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Ascentage Pharma Group International | 16.28B |
| Keymed Biosciences | 15.85B |
| Zai Lab | 15.32B |
| Ascletis Pharma | 14.65B |
| Nanjing Leads Biolabs | 13.07B |
| Guangzhou Innogen Pharmaceutical Group | 10.20B |
| HBM Holdings | 9.78B |
| CStone Pharmaceuticals | 9.72B |